

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Appl. No. 09/719,423

B2 11 (Amended). A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.

Please add the following new claims:

B3 16. A compound according to claim 3 in which the B1 lysine residue is Phe.

17. A compound according to claim 2 in which the insulin is human insulin.

18. A compound according to claim 3 in which the insulin is human insulin.

IN THE ABSTRACT:

Please add the following Abstract of the Disclosure

B4 A novel analogue of insulin has covalently conjugated thereto, preferably at the B1 residue, 3, 3', 5'-triiodothyroxine. The conjugate is believed to be hepatoselective, whilst it retains insulin receptor binding properties.